Vaxil announces key US Patent and Trademark Office Notice of Allowance for its immunotherapy
![](/46/pdcnewsitem/04/21/16/vaxil.jpg)
First US Patent issued to Vaxil since the company began developing its immunotherapies 10 years ago.
Vaxil Bio has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent providing broad coverage over Vaxil's immunotherapy platform and its lead product, Orphan Drug Designated Immucin.
This will become the first US Patent issued to Vaxil since the company began developing its immunotherapies 10 years ago. ImMucin is an immunotherapy intended to train a patient's immune system, particularly T-cells and antibodies, to attack cancer cells via a specific domain, called the signal peptide, of the tumour marker MUC1. This domain bears significant advantages as an immunotherapeutic modality including its presence on approximately 90% of all cancer types. The notice indicates the patentability of claims covering the ImMucin peptide as well as claims reciting methods for treating or inhibiting cancer using the ImMucin peptide. This is a highly important addition to Vaxil's existing patent portfolio and strengthens the company's ability to protect its proprietary technologies as it continues rigorous testing and advancement of ImMucin. Moreover, it positions Vaxil as the only player able to use the 21-mer peptide known as ImMucin for all MUC1 positive tumours. Immucin is the first product generated from Vaxil's proprietary VaxHit platform, and has been awarded Orphan Drug Status from the FDA and EMA. Vaxil believes there is potential for VaxHit to generate additional immunotherapy products targeting the signal peptide domains of other prominent tumour markers.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance